Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. The company's products are used by hospitals, clinical and medical research laboratories, blood and dialysis centers, rehabilitation centers, nursing homes, doctors' offices and by patients, at home, under physician supervision.
ONE BAXTER PKWY DF2-1W DEERFIELD, IL 60015, USA Phone: 8479482000 Fax: 847-948-2016 Web: http://www.baxter.com
Industry:MED PRODUCTS Sector: Medical Fiscal Year End:December Last Reported Quarter:03/31/12 Next EPS Date:07/19/12
Capital Structure Solvency and Cash Flow
Cash Flow and Balance Sheet
Baxter exited 3Q10 with $2.8 billion in cash compared with $2.3 billion at the end of the sequentially prior quarter.
In 3Q10, cash flows from operations were slightly over $1 billion compared with $783 million in the sequentially prior quarter. Capital expenditure was $232 million in the reported quarter.
Outlook: Baxter expects to generate cash flow from operations of about $2.8 billion in FY10.
Share Repurchase: During 3Q10, the Company repurchased 3.6 million common shares costing approximately $161 million.
Last edited Sun Jan 02, 2011 08:35 AM by SreelaBose (Zacks Investment Research)
Governance Social Responsibility and Employee Relations
